Literature DB >> 9027018

[Heparin-induced thrombocytopenia Type II (HIT II) A fatal complication of heparin use for thromboembolism prevention].

G Hobbensiefken1, B Driller, V Studtmann, K Kunz, G Lehrbach.   

Abstract

Heparin-induced thrombocytopenia type II (HIT II) is the most severe complication during prophylactic treatment with low doses of heparin. Five cases demonstrate the life-threatening consequences of this immune-mediated thromboembolic disease. In order to improve prognosis it is most important to start therapy just before diagnosis is assured by laboratory tests. First choice treatment is the low-molecular-weight heparinoid Orgaran. In patients with an episode of HIT II both low-molecular-weight heparin and unfractionated heparin will be contraindicated for a life time.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9027018

Source DB:  PubMed          Journal:  Unfallchirurgie        ISSN: 0340-2649


  17 in total

1.  Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor.

Authors:  T Matsuo; K Kario; Y Chikahira; K Nakao; T Yamada
Journal:  Br J Haematol       Date:  1992-11       Impact factor: 6.998

Review 2.  Antigen generation in heparin-associated thrombocytopenia: the nonimmunologic type and the immunologic type are closely linked in their pathogenesis.

Authors:  A Greinacher
Journal:  Semin Thromb Hemost       Date:  1995       Impact factor: 4.180

Review 3.  Heparin-induced thrombocytopenia.

Authors:  B H Chong
Journal:  Br J Haematol       Date:  1995-03       Impact factor: 6.998

4.  Heparin-induced thrombocytopenia and thrombosis.

Authors:  R H Aster
Journal:  N Engl J Med       Date:  1995-05-18       Impact factor: 91.245

5.  Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay.

Authors:  A Greinacher; J Amiral; V Dummel; A Vissac; V Kiefel; C Mueller-Eckhardt
Journal:  Transfusion       Date:  1994-05       Impact factor: 3.157

6.  Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.

Authors:  T E Warkentin; M N Levine; J Hirsh; P Horsewood; R S Roberts; M Gent; J G Kelton
Journal:  N Engl J Med       Date:  1995-05-18       Impact factor: 91.245

7.  Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172)

Authors:  H N Magnani
Journal:  Thromb Haemost       Date:  1993-10-18       Impact factor: 5.249

8.  Heparin-associated thrombocytopenia: the antibody is not heparin specific.

Authors:  A Greinacher; I Michels; C Mueller-Eckhardt
Journal:  Thromb Haemost       Date:  1992-05-04       Impact factor: 5.249

9.  Heparin-associated thrombocytopenia (HAT)--still a diagnostic and therapeutical problem in clinical practice.

Authors:  S Kleinschmidt; U T Seyfert
Journal:  Angiology       Date:  1995-01       Impact factor: 3.619

10.  Heparin-associated thrombocytopenia: successful therapy with the heparinoid Org 10172 in a patient showing cross-reaction to LMW heparins.

Authors:  A Greinacher; W Drost; I Michels; J Leitl; M Gottsmann; H J Kohl; M Glaser; C Mueller-Eckhardt
Journal:  Ann Hematol       Date:  1992-01       Impact factor: 3.673

View more
  1 in total

1.  [Heparin-induced thrombocytopenia with unfractionated heparin. A prospective study of inpatient treatment of internal medicine patients].

Authors:  H Heidrich; K Kahl; C Penninger; B Bechstein; M Birkenmaier; S Dressler; C Fahrig; J Helmis; G Herman; U von Knobloch; M Ladleif; K Meier; M Rudolph; B Schlich; M Wanke; B Zwernemann
Journal:  Med Klin (Munich)       Date:  1998-06-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.